Evidence map›Paper›PMID 40433420›Full record

ArticleInternational journal of endocrinology and metabolism2024

Evaluation of the Effects of Incorporating Long-Acting Subcutaneous Insulin Into the Standard Treatment Protocol for Diabetic Ketoacidosis in Children.

Fatemeh Saffari, Ali Homaei, Venus Chegini, Amir Javadi, Victoria Chegini

Abstract read
In one paragraph

Article in International journal of endocrinology and metabolism, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Fatemeh SaffariDepartment of Pediatrics, Children Growth Research Center, Research Institute for Prevention Non-communicable Diseases, School of Medicine, Qazvin University of Medical Sciences, Qazvin, Iran.ORCID https://orcid.org/0000-0002-8366-5205
Ali HomaeiBeth Israel Deaconess Medical Center, Harvard Medical School, Harvard University, Boston, MA, US.
Venus CheginiDepartment of Obstetrics and Gynecology, School of Medicine, Qazvin University of Medical Sciences, Qazvin, Iran.ORCID https://orcid.org/0000-0002-8031-5840
Amir JavadiDepartment of Community Medicine, Medical Microbiology Research Center, School of Medicine, Qazvin University of Medical Sciences, Qazvin, Iran.ORCID https://orcid.org/0000-0001-7715-4583
Victoria CheginiDepartment of Pediatrics, Children Growth Research Center, Research Institute for Prevention Non-communicable Diseases, School of Medicine, Qazvin University of Medical Sciences, Qazvin, Iran.ORCID https://orcid.org/0000-0001-7527-4389

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Despite the progress made in the treatment of type 1 diabetes, the incidence of diabetic ketoacidosis (DKA) in children is still increasing, and its management requires hospitalization in the pediatric intensive care unit (PICU). It is important to find a new and low-risk treatment method to shorten the recovery time from DKA. Objectives: This study aimed to evaluate the effectiveness and safety of integrating two different types of long-acting subcutaneous insulin into the standard treatment for DKA in children. Methods: The study was conducted in the PICU, and comprehensive monitoring was performed throughout the process. Patients aged between 2 and 15 years were divided into three groups: Two intervention groups receiving the addition of two types of long-acting insulin, Detemir and Glargine, to the standard treatment, and a control group. Each group consisted of 36 individuals. The impact of the intervention on the recovery time from DKA and the potential complications were investigated in all three groups. Results: The analysis of the results revealed a significant difference in the duration of exiting the acute phase among the groups. Additionally, the post-hoc test demonstrated that the recovery time for ketoacidosis in the Detemir arm was significantly shorter than in the standard arm (P = 0.008). However, it is important to note that there were no significant differences in the occurrence of common complications among the three study groups. Conclusions: Based on the findings, it appears that incorporating specific types of long-acting subcutaneous insulin into the standard treatment of DKA in children leads to a reduction in the resolution time of the acute phase of ketoacidosis. Importantly, this approach does not introduce additional complications. Consequently, it has the potential to optimize resource allocation and enhance patient care by freeing up beds in the PICU.

Indexed as

Basal InsulinChildrenClinical TrialDiabetes Type 1Diabetic KetoacidosisInsulin AnaloguesPediatric Intensive Care Unit

Identifiers

PMID40433420
PMCPMC12106965

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.